Hospitals across the UK are failing to test all bowel cancer patients at the time of their diagnosis for a genetic condition called Lynch syndrome, which significantly increases the risk of developing cancer over a lifetime.
News
Ablynx’ vobarilizumab fails in lupus trial
Ablynx’ vobarilizumab has failed to hit targets in a mid-stage trial assessing its safety and effectiveness as a treatment for systemic lupus erythematosus (SLE).
GSK to buy-out Novartis’ stake in consumer health JV
GlaxoSmithKline is buying Novartis’ stake in the firms’ consumer healthcare unit, the announcement coming just days after the drug giant said it would not pursue acquisition of Pfizer’s consumer healthcare business.
Industry welcomes progress on Brexit
Pharmaceutical industry representatives have applauded the decision to progress Brexit negotiations to the next phase, with the UK and EU having agreed the terms of the transition period.
Shire links with NanoMedSyn to work on new ERT
Shire has linked with US biotech NanoMedSyn to evaluate a potential enzyme replacement therapy (ERT) for an undisclosed lysosomal storage disorder.
EU clears first allogeneic stem cell therapy
TiGenix and Takeda’s Alofisel has become the first allogeneic stem cell therapy to be approved for use across the European Union.
GSK no longer vying for Pfizer’s consumer assets
GlaxoSmithKline has revealed that it will not bid for Pfizer’s consumer healthcare business, pulling out of the process just days after rival suitor Reckit Benckiser stepped away from a potential deal.
Tasigna cleared for use in children with rare leukemia
The US Food and Drug Administration is allowing use of Novartis’ Tasigna to treat paediatric patients with a rare form of leukaemia.
EU approves AZ’ potassium binder for hyperkalaemia
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
US, EU filings imminent for Novartis’ MS therapy siponimod
Novartis’ experimental multiple sclerosis therapy siponimod is on the brink of being filed in the US.
NEJM publishes venetoclax/rituximab data
A combination of venetoclax and rituximab being developed by AbbVie and Roche/Genentech significantly improved progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL), shows data published by the New England Journal of Medicine.
Psoriasis patients get NHS access to LEO Pharma’s Kyntheum
Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the use of LEO Pharma’s Kyntheum as an option for treating severe plaque psoriasis.
UK patients get early access to Akcea’s volanesorsen
Akcea Therapeutics’ volanesorsen will be available to eligible patients in the UK before it is officially licensed in the EU, having been granted entry to the country’s Early Access to Medicines Scheme.
US green lights new biologic for psoriasis
The US Food and Drug Administration has approved Sun Pharma’s Ilumya as a new treatment option for adults with moderate-to-severe plaque psoriasis.
GSK trials Benlysta/rituximab combo for lupus
GlaxoSmithKline has kicked off a Phase III trial assessing its lupus drug Benlysta in combination with rituximab in adult patients with the condition.
